View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward online CME activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, and Prometheus Laboratories Inc.

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based


Activity Overview

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward features case-based discussions about standard and emerging therapies for renal cell carcinoma (RCC). Interactive clinical vignettes are followed by brief video interviews with leading experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians who treat patients with RCC.

CME Activity Table of Contents

  • Targeted Therapy in the Adjuvant and Relapsed Metastatic Settings
    Robert Figlin, MD
  • Immunotherapy in RCC in 2017
    David McDermott, MD
  • Informed Therapeutic Sequencing
    Sumanta K. Pal, MD
  • Non‒Clear Cell RCC
    Bernard Escudier, MD
  • Looking Ahead in RCC
    Toni Choueiri, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the management of RCC.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Discuss the biology of RCC and clinical circumstances that inform switching and sequencing of therapies in the care of patients with these malignancies
  • Assess targeted approaches for RCC management, the mechanistic rationale for treatment combinations, and emerging evidence concerning these strategies
  • Describe the role of immunotherapy in the setting of RCC in the context of trial data, real-world experience, and monitoring
  • Apply best practices to manage treatment-related toxicities and assess their impact on clinical decision making to optimize sequencing in the management of RCC
  • Evaluate clinical scenarios that may soon impact the RCC treatment landscape, including evolving compounds, combinations, and biomarkers

Faculty, Staff, and Planners' Disclosures

Program Chair

Toni Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute/Brigham and Women's Hospital
The Jerome and Nancy Kohlberg Endowed Chair
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosure: Grant/Research Support: Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton, Celldex; Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Eisai, Bristol-Myers Squibb, Merck, Roche, Prometheus Laboratories Inc.


Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Gustave Roussy Institute
Paris, France

Disclosure: Consultant: Pfizer, Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences Director
Division of Hematology Oncology
Deputy Director Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

David F. McDermott, MD
Leader, Dana-Farber Harvard Cancer Center
Kidney Cancer Program Director
Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center Associate Professor of Medicine
Harvard Medical School
Boston Massachusetts

Disclosure: Grant/Research Support: Prometheus Laboratories; Consultant: Bristol-Myers Squibb, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm, Genentech

Sumanta Kumar Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of hope
Duarte, California

Disclosure: Consultant: Novartis, Pfizer, Astellas, Genentech, GlaxoSmithKline, Bristol-Myers Squibb, Exelisis; Speaker's Bureau: Genentech

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By